Johnson & Johnson announces FDA approval of INLEXZO

Johnson & Johnson announced the U.S. FDA approved INLEXZO, a new, potentially practice-changing approach for treating patients with certain types of bladder cancer, addressing the need for additional options following unsuccessful BCG therapy and for patients refusing or ineligible for bladder removal surgery. INLEXZO, previously referred to as TAR-200, is indicated for the treatment of adult patients with Bacillus Calmette-Guerin-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors.